Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Initial research about inhibiting CD47 signaling on tumor cells has meant a focus on oncology drug development. New research shows that inhibiting this cell surface molecule could be used to treat atherosclerosis.

Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.

The project that prompted the formation of Serodus AS is no longer the driving force of this start-up company. But the founding research did spark a deal that brought the firm a similar but more advanced asset, now one of three the firm is developing for cardiovascular indications ranging from high systolic blood pressure to atrial fibrillation to heart failure. Serodus in-licensed its lead candidate, a peptide classified as an opioid receptor agonist from Zealand Pharma, which took the compound through several clinical trials in both acute and chronic heart failure. Serodus thinks it could potentially develop a 5-HT-4 receptor antagonist it calls SER102 for atrial fibrillation that occurs in connection with surgery.